<DOC>
	<DOCNO>NCT00002772</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know regimen chemotherapy follow peripheral stem cell transplantation effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy plus peripheral stem cell transplantation treat woman undergone surgery breast cancer .</brief_summary>
	<brief_title>S9623 , Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare disease free survival overall survival woman operable breast cancer least 4 positive axillary lymph node treat intensive sequential chemotherapy doxorubicin , paclitaxel , cyclophosphamide versus standard dose doxorubicin cyclophosphamide follow high dose STAMP I ( cyclophosphamide , cisplatin , carmustine ) STAMP V ( cyclophosphamide , carboplatin , thiotepa ) autologous stem cell rescue . II . Compare toxic effect regimens patient population . III . Measure breast cancer cell content peripheral blood progenitor cell ( PBPC ) fraction patient randomize PBPC support arm correlate result disease free survival , survival , pattern relapse patient . OUTLINE : This randomize , multicenter study . Patients stratify center , primary treatment ( mastectomy alone vs mastectomy plus radiotherapy follow chemotherapy v breast conserving surgery plus radiotherapy follow chemotherapy ) , menopausal status ( premenopausal v postmenopausal ) , estrogen and/or progesterone receptor status ( positive v negative v unknown ) , N2 disease ( yes v ) , T3 disease ( yes v ) , myeloablative chemotherapy regimen ( STAMP I vs STAMP V ) , source progenitor cell ( marrow vs peripheral blood v ) . Patients randomize 1 2 treatment arm : Arm I : Patients receive doxorubicin IV 1 hour day 1 , 15 , 29 , paclitaxel IV 24 hour day 43 , 57 , 71 , cyclophosphamide IV 1 hour day 85 , 99 , 113 . Patients receive filgrastim ( G-CSF ) subcutaneously day 3-10 , 17-24 , 31-38 , 45-52 , 59-66 , 73-80 , 87-94 , 101-108 , 115-122 . Arm II : Mobilization chemotherapy : Patients receive doxorubicin IV 1 hour cyclophosphamide IV 1 hour day 1 , 22 , 43 , 64 . Harvest : Patients undergo harvest autologous bone marrow and/or peripheral blood stem cell ( PBSC ) . Patients undergo harvest PBSC alone receive mobilization chemotherapy receive hematopoietic growth factor prior harvest . High dose myeloablative chemotherapy : Patients receive STAMP I OR STAMP V : STAMP I : Patients receive cyclophosphamide IV 1 hour cisplatin IV 24 hour day -6 -4 carmustine IV 2 hour day -3 . STAMP V : Patients receive cyclophosphamide IV 24 hour , carboplatin IV 24 hour , thiotepa IV 24 hour day -7 -4 . Transplantation : Autologous bone marrow and/or PBSC reinfused day 0 . Both arm : Patients postmenopausal hormone receptor positive disease receive oral tamoxifen daily begin 4 week completion chemotherapy continue 5 year . Patients underwent breast conserving surgery receive locoregional radiotherapy 5 day week 4.5-5.5 week begin 4-6 week completion chemotherapy . Patients underwent modified radical mastectomy may receive locoregional radiotherapy 5 day week 5 week discretion physician . Patients follow every 4 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 1,000 patient ( 500 per arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma breast least 4 involved axillary and/or intramammary lymph nod No known T4 , N3 , M1 disease Dermal lymphatic involvement without clinical inflammatory change ( edema , peau d'orange , erythema ) allow Must undergone breast conserving surgery modify radical mastectomy plus axillary lymph node dissection Surgical margin negative invasive noninvasive ductal carcinoma At least 10 node sample No 12 week since definitive surgery Synchronous bilateral breast carcinoma allow : Diagnosed within 4 week initial histologic diagnosis One breast meet eligibility criterion Other breast few 10 involved node N3 T4 Both breast treat modified radical mastectomy breast conserving surgery axillary node dissection Concurrent registration S9719 Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Adult Sex : Female Menopausal status : Any status Performance status : SWOG 0 1 Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 1.5 time ULN Hepatitis C status require Renal : Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction rest least 45 % MUGA No EKG abnormalities unless clear cardiologist No uncontrolled significant cardiac disease No congestive heart failure No second third degree heart block serious cardiac conduction abnormality No atrial ventricular arrhythmia No requirement medication know affect cardiac conduction unless : Given reason heart failure arrhythmia Cleared cardiologist Pulmonary : FVC FEV1 least 60 % predict DLCO least 60 % predict Other : HIV negative Hepatitis B surface antigen status require No serious medical psychiatric illness would preclude informed consent study participation No second malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , intraductal lobular carcinoma breast ( diagnosed time ) Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No prior hormonal therapy breast cancer Radiotherapy : No prior radiotherapy breast Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>